Loading Events

Upcoming Events › Grant

Events Search and Views Navigation

Event Views Navigation

December 2019

Rolling Basis: Alzheimer’s Drug Discovery Foundation

December 31

PROPOSALS ACCEPTED ON A ROLLING BASIS
ADDF/NIH
Supports NIA and NINDS grant proposals in NIH format that were scored but not funded, which fall within our mission and research priorities.
Conference Funding
Supports scientific conferences that are relevant to our mission with grants up to $10,000.

Find out more »

January 2020

ANGEL (Advanced Neurotherapeutic Grant of Excellence) Award

January 1, 2020

Sponsor: International Rett Syndrome Foundation (IRSF)
Due Date: Applications accepted on a rolling basis
Award: Up to $600,000 over two years

Find out more »

Cycle 1: Whitehall Foundation Grants-In-Aid

January 1, 2020

Sponsor: Whitehall Foundation, Inc.
LOI Due Date: January 15, 2020
Application Due Date: June 1, 2020
Award: Grants-in-Aid are awarded for a one-year period and do not exceed $30,000.

Find out more »

Healthcare Research by Community Physicians

January 1, 2020

Sponsor: Physicans’ Services Incorporated Foundation

Due Date: Applications accepted on a rolling basis

Award: Grants up to $20,000 are available to cover the costs of the data gathering and analysis,
support staff and preparation of reports. Up to an additional $500 will be provided for travel
costs incurred in presenting papers on the results of a community practice study.

 

Find out more »

Cycle 2: NIH R41, R42, R43, R44, U43, U44

January 5, 2020

DUE DATE: JANUARY 5, 2020

BRAIN Initiative: Development, Optimization, and Validation of Novel Tools and Technologies for Neuroscience Research (SBIR)(R43/R44 Clinical Trial Not Allowed): This Funding Opportunity Announcement (FOA) which uses the STTR grant mechanism, will support to support the development of novel neuroscience tools and technologies in order to better understand the structure and function of brain circuits- a major goal of the BRAIN Initiative. This FOA will support further development of neurotechnologies developed through the BRAIN initiative or through other funding programs in preparation for commercial dissemination. According to statutory guidelines, total funding support (direct costs, indirect costs, fee) normally may not exceed $150,000 for Phase I awards and $1,000,000 for Phase II awards. With appropriate justification from the applicant, Congress will allow awards to exceed these amounts by up to 50% as a hard cap ($225,000 for Phase I and $1,500,000 for Phase II). However, NIH has received a waiver from SBA, as authorized by statute, to exceed the hard cap of $225,000 for Phase I or $1,500,000 for Phase II for specific topics.

BRAIN Initiative: Development, Optimization, and Validation of Novel Tools and Technologies for Neuroscience Research (STTR)(R41/R42 Clinical Trial Not Allowed): The purpose of this funding opportunity announcement (FOA) is to support the development of novel tools and technologies through the Small Business Technology Transfer (STTR) program to advance the field of neuroscience research. Total funding support (direct costs, indirect costs, fee) normally may not exceed $150,000 for Phase I awards and $1,000,000 for Phase II awards. With appropriate justification from the applicant, Congress will allow awards to exceed these amounts by up to 50 percent ($225,000 for Phase I and $1,500,000 for Phase II).

Find out more »

Cycle 1: Whitehall Foundation Research Grants

January 15, 2020

Sponsor: Whitehall Foundation, Inc.
LOI Due Date: January 15, 2020
Application Due Date: June 1, 2020
Award: Research grants normally range from $30,000 to $75,000 per year for up to three years.

Find out more »

February 2020

NIH R21, R03

February 16, 2020
|Recurring Event (See all)

One event on February 16, 2020 at 12:00 am

One event on June 16, 2020 at 12:00 am

One event on October 16, 2020 at 12:00 am

DUE DATES: 

  • Cycle 3: October 16, 2019 by 5 PM of local organization time
  • Cycle 1: February 16, 2020 by 5 PM of local organization time
  • Cycle 2: June 16, 2020 by 5 PM of local organization time

Biobehavioral and Technological Interventions to Attenuate Cognitive Decline in Individuals with Cognitive Impairment or Dementia: 
The combined budget for direct costs for the two-year project period may not exceed $275,000.  No more than $200,000 may be requested in any single year.
Small Research Grants for Analyses of Gabriella Miller Kids First Pediatric Research Data (R03 Clinical Trial Not Allowed)
The combined budget for direct costs for the two year project period may not exceed $200,000.
Biobehavioral and Technological Interventions to Attenuate Cognitive Decline in Individuals with Cognitive Impairment or Dementia (R21)
The combined budget for direct costs for the two-year project period may not exceed $275,000.  No more than $200,000 may be requested in any single year.
Chronic Condition Self-Management in Children and Adolescents (R21 Clinical Trial Optional)
Direct costs are limited to $275,000 over an R21 two-year period, with no more than $200,000 in direct costs allowed in any single year.

Find out more »

March 2020

AES Seed Grant Program 

March 23, 2020
|Recurring Event (See all)

One event on March 23, 2020 at 12:00 am

Sponsor: American Epilepsy Society
Due Date: September 22, 2019 or March 23, 2020
Award: The AES Seed Grant Program provides support to established investigators to pursue new and innovative directions in epilepsy research, bring new research methods to their research programs, or begin new collaborations with other investigators in epilepsy or in different, complementary disciplines. Seed Grants may provide up to $20,000 for one year for direct costs only, and they may not be renewed.

Find out more »

April 2020

Cycle 3: NIH R41, R42, R43, R44, U43, U44

April 5, 2020

DUE DATE: APRIL 5, 2020

BRAIN Initiative: Development, Optimization, and Validation of Novel Tools and Technologies for Neuroscience Research (SBIR)(R43/R44 Clinical Trial Not Allowed): This Funding Opportunity Announcement (FOA) which uses the STTR grant mechanism, will support to support the development of novel neuroscience tools and technologies in order to better understand the structure and function of brain circuits- a major goal of the BRAIN Initiative. This FOA will support further development of neurotechnologies developed through the BRAIN initiative or through other funding programs in preparation for commercial dissemination. According to statutory guidelines, total funding support (direct costs, indirect costs, fee) normally may not exceed $150,000 for Phase I awards and $1,000,000 for Phase II awards. With appropriate justification from the applicant, Congress will allow awards to exceed these amounts by up to 50% as a hard cap ($225,000 for Phase I and $1,500,000 for Phase II). However, NIH has received a waiver from SBA, as authorized by statute, to exceed the hard cap of $225,000 for Phase I or $1,500,000 for Phase II for specific topics.

BRAIN Initiative: Development, Optimization, and Validation of Novel Tools and Technologies for Neuroscience Research (STTR)(R41/R42 Clinical Trial Not Allowed): The purpose of this funding opportunity announcement (FOA) is to support the development of novel tools and technologies through the Small Business Technology Transfer (STTR) program to advance the field of neuroscience research. Total funding support (direct costs, indirect costs, fee) normally may not exceed $150,000 for Phase I awards and $1,000,000 for Phase II awards. With appropriate justification from the applicant, Congress will allow awards to exceed these amounts by up to 50 percent ($225,000 for Phase I and $1,500,000 for Phase II).

Find out more »

June 2020

NIH R21, R03

June 16, 2020
|Recurring Event (See all)

One event on February 16, 2020 at 12:00 am

One event on June 16, 2020 at 12:00 am

One event on October 16, 2020 at 12:00 am

DUE DATES: 

  • Cycle 3: October 16, 2019 by 5 PM of local organization time
  • Cycle 1: February 16, 2020 by 5 PM of local organization time
  • Cycle 2: June 16, 2020 by 5 PM of local organization time

Biobehavioral and Technological Interventions to Attenuate Cognitive Decline in Individuals with Cognitive Impairment or Dementia: 
The combined budget for direct costs for the two-year project period may not exceed $275,000.  No more than $200,000 may be requested in any single year.
Small Research Grants for Analyses of Gabriella Miller Kids First Pediatric Research Data (R03 Clinical Trial Not Allowed)
The combined budget for direct costs for the two year project period may not exceed $200,000.
Biobehavioral and Technological Interventions to Attenuate Cognitive Decline in Individuals with Cognitive Impairment or Dementia (R21)
The combined budget for direct costs for the two-year project period may not exceed $275,000.  No more than $200,000 may be requested in any single year.
Chronic Condition Self-Management in Children and Adolescents (R21 Clinical Trial Optional)
Direct costs are limited to $275,000 over an R21 two-year period, with no more than $200,000 in direct costs allowed in any single year.

Find out more »

October 2020

NIH R21, R03

October 16, 2020
|Recurring Event (See all)

One event on February 16, 2020 at 12:00 am

One event on June 16, 2020 at 12:00 am

One event on October 16, 2020 at 12:00 am

DUE DATES: 

  • Cycle 3: October 16, 2019 by 5 PM of local organization time
  • Cycle 1: February 16, 2020 by 5 PM of local organization time
  • Cycle 2: June 16, 2020 by 5 PM of local organization time

Biobehavioral and Technological Interventions to Attenuate Cognitive Decline in Individuals with Cognitive Impairment or Dementia: 
The combined budget for direct costs for the two-year project period may not exceed $275,000.  No more than $200,000 may be requested in any single year.
Small Research Grants for Analyses of Gabriella Miller Kids First Pediatric Research Data (R03 Clinical Trial Not Allowed)
The combined budget for direct costs for the two year project period may not exceed $200,000.
Biobehavioral and Technological Interventions to Attenuate Cognitive Decline in Individuals with Cognitive Impairment or Dementia (R21)
The combined budget for direct costs for the two-year project period may not exceed $275,000.  No more than $200,000 may be requested in any single year.
Chronic Condition Self-Management in Children and Adolescents (R21 Clinical Trial Optional)
Direct costs are limited to $275,000 over an R21 two-year period, with no more than $200,000 in direct costs allowed in any single year.

Find out more »
+ Export Events